Institute for Hygiene and Microbiology, University of Wuerzburg, Wuerzburg, Germany.
Institute of Microbiology, DRK Kliniken Berlin, Berlin, Germany.
Sci Rep. 2017 Oct 26;7(1):14127. doi: 10.1038/s41598-017-14367-z.
Tuberculosis (TB) and the spread of Mycobacterium tuberculosis complex (MTBC) strains resistant against rifampin (RIF) and isoniazid (INH) pose a serious threat to global health. However, rapid and reliable MTBC detection along with RIF/INH susceptibility testing are challenging in low prevalence countries due to the higher rate of false positives. Here, we provide the first performance data for the artus MTBC PCR assay in a low prevalence setting. We analyze 1323 respiratory and 311 non-respiratory samples with the artus MTBC PCR assay as well as by mycobacterial culture and microscopy. We propose retesting of specimens in duplicate and consideration of a determined cycle-threshold value cut-off greater than 34, as this significantly increases accuracy, specificity, and negative predictive value without affecting sensitivity. Furthermore, we tested fourteen MTBC positive samples with the GenoType MTBDRplus test and demonstrate that using an identical DNA extraction protocol for both assays does not impair downstream genotypic testing for RIF and INH susceptibility. In conclusion, our procedure optimizes the use of the artus MTB assay with workload efficient methods in a low incidence setting. Combining the modified artus MTB with the GenoType MTBDRplus assays allows rapid and accurate detection of MTBC and RIF/INH resistance.
结核病(TB)和耐利福平(RIF)和异烟肼(INH)的结核分枝杆菌复合群(MTBC)菌株的传播对全球健康构成严重威胁。然而,由于假阳性率较高,在低流行国家进行快速可靠的 MTBC 检测以及 RIF/INH 药敏试验具有挑战性。在这里,我们提供了 artus MTBC PCR 检测在低流行环境中的性能数据。我们分析了 1323 份呼吸道样本和 311 份非呼吸道样本,采用 artus MTBC PCR 检测、分枝杆菌培养和显微镜检查。我们建议对标本进行重复检测,并考虑确定的循环阈值(Ct)值截止值大于 34,因为这显著提高了准确性、特异性和阴性预测值,而不会影响敏感性。此外,我们用 GenoType MTBDRplus 测试了 14 份 MTBC 阳性样本,并证明在两种检测中使用相同的 DNA 提取方案不会损害下游对 RIF 和 INH 敏感性的基因分型检测。总之,我们的程序优化了 artus MTB 检测在低发病率环境中的使用,采用了高效的工作负载方法。将改良的 artus MTB 与 GenoType MTBDRplus 检测相结合,可快速准确地检测 MTBC 和 RIF/INH 耐药性。